TY - JOUR
T1 - Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease
T2 - Results From Two International Databases
AU - Brenner, Erica J.
AU - Pigneur, Bénédicte
AU - Focht, Gili
AU - Zhang, Xian
AU - Ungaro, Ryan C.
AU - Colombel, Jean Frederic
AU - Turner, Dan
AU - Kappelman, Michael D.
AU - Ruemmele, Frank M.
N1 - Publisher Copyright:
© 2021 AGA Institute
PY - 2021/2
Y1 - 2021/2
N2 - The coronavirus disease 2019 (COVID-19) pandemic caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents most often with mild clinical symptoms, but the severe forms are of major concern.1 SARS-CoV-2 enters human cells via the angiotensin-converting enzyme 2 receptor, expressed on epithelial and endothelial cells.2 Because the highest angiotensin-converting enzyme 2 expression is in the terminal ileum and colon, and up-regulated further during inflammation, and many COVID-19 patients experience gastrointestinal symptoms, longitudinal data are necessary to determine whether inflammatory bowel disease (IBD) patients are at risk for severe or complicated COVID-19. A recent analysis in IBD patients from the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registry showed older age, steroid medication, and comorbidities as risk factors for severe evolution, and the same study showed that the 29 IBD patients younger than age 20 had only mild disease courses.3 This report describes the disease course of COVID-19 in an expanded sample of pediatric IBD patients from 2 international databases.
AB - The coronavirus disease 2019 (COVID-19) pandemic caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents most often with mild clinical symptoms, but the severe forms are of major concern.1 SARS-CoV-2 enters human cells via the angiotensin-converting enzyme 2 receptor, expressed on epithelial and endothelial cells.2 Because the highest angiotensin-converting enzyme 2 expression is in the terminal ileum and colon, and up-regulated further during inflammation, and many COVID-19 patients experience gastrointestinal symptoms, longitudinal data are necessary to determine whether inflammatory bowel disease (IBD) patients are at risk for severe or complicated COVID-19. A recent analysis in IBD patients from the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registry showed older age, steroid medication, and comorbidities as risk factors for severe evolution, and the same study showed that the 29 IBD patients younger than age 20 had only mild disease courses.3 This report describes the disease course of COVID-19 in an expanded sample of pediatric IBD patients from 2 international databases.
UR - http://www.scopus.com/inward/record.url?scp=85097219061&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2020.10.010
DO - 10.1016/j.cgh.2020.10.010
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.shortsurvey???
C2 - 33059040
AN - SCOPUS:85097219061
SN - 1542-3565
VL - 19
SP - 394-396.e5
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 2
ER -
